The global Antivenom market size was valued at US$ 1032 million in 2024 and is forecast to a readjusted size of USD 1363 million by 2031 with a CAGR of 4.1% during review period.
Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings. They are only recommended if there is significant toxicity or a high risk of toxicity. The specific antivenom needed depends on the species involved. It is given by injection.
CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.
This report is a detailed and comprehensive analysis for global Antivenom market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Antivenom market size and forecasts, in consumption value ($ Million), sales quantity (K Vials), and average selling prices (USD/Vial), 2020-2031
Global Antivenom market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Vials), and average selling prices (USD/Vial), 2020-2031
Global Antivenom market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Vials), and average selling prices (USD/Vial), 2020-2031
Global Antivenom market shares of main players, shipments in revenue ($ Million), sales quantity (K Vials), and ASP (USD/Vial), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Antivenom
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Antivenom market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include CSL, Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Antivenom market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Polyvalent antivenom
Monovalent antivenom
麻豆原创 segment by Application
Non-profit Institutions
Hospitals and Clinic
Major players covered
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Antivenom product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Antivenom, with price, sales quantity, revenue, and global market share of Antivenom from 2020 to 2025.
Chapter 3, the Antivenom competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Antivenom breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Antivenom market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Antivenom.
Chapter 14 and 15, to describe Antivenom sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Antivenom Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Polyvalent antivenom
1.3.3 Monovalent antivenom
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Antivenom Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Non-profit Institutions
1.4.3 Hospitals and Clinic
1.5 Global Antivenom 麻豆原创 Size & Forecast
1.5.1 Global Antivenom Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Antivenom Sales Quantity (2020-2031)
1.5.3 Global Antivenom Average Price (2020-2031)
2 Manufacturers Profiles
2.1 CSL
2.1.1 CSL Details
2.1.2 CSL Major Business
2.1.3 CSL Antivenom Product and Services
2.1.4 CSL Antivenom Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 CSL Recent Developments/Updates
2.2 Merck
2.2.1 Merck Details
2.2.2 Merck Major Business
2.2.3 Merck Antivenom Product and Services
2.2.4 Merck Antivenom Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Merck Recent Developments/Updates
2.3 BTG
2.3.1 BTG Details
2.3.2 BTG Major Business
2.3.3 BTG Antivenom Product and Services
2.3.4 BTG Antivenom Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 BTG Recent Developments/Updates
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Antivenom Product and Services
2.4.4 Pfizer Antivenom Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Pfizer Recent Developments/Updates
2.5 Haffkine Bio-Pharmaceutical
2.5.1 Haffkine Bio-Pharmaceutical Details
2.5.2 Haffkine Bio-Pharmaceutical Major Business
2.5.3 Haffkine Bio-Pharmaceutical Antivenom Product and Services
2.5.4 Haffkine Bio-Pharmaceutical Antivenom Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Haffkine Bio-Pharmaceutical Recent Developments/Updates
2.6 Rare Disease Therapeutics
2.6.1 Rare Disease Therapeutics Details
2.6.2 Rare Disease Therapeutics Major Business
2.6.3 Rare Disease Therapeutics Antivenom Product and Services
2.6.4 Rare Disease Therapeutics Antivenom Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Rare Disease Therapeutics Recent Developments/Updates
2.7 Flynn Pharma
2.7.1 Flynn Pharma Details
2.7.2 Flynn Pharma Major Business
2.7.3 Flynn Pharma Antivenom Product and Services
2.7.4 Flynn Pharma Antivenom Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Flynn Pharma Recent Developments/Updates
2.8 Vins Bioproducts
2.8.1 Vins Bioproducts Details
2.8.2 Vins Bioproducts Major Business
2.8.3 Vins Bioproducts Antivenom Product and Services
2.8.4 Vins Bioproducts Antivenom Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Vins Bioproducts Recent Developments/Updates
2.9 Bharat Serums and Vaccines
2.9.1 Bharat Serums and Vaccines Details
2.9.2 Bharat Serums and Vaccines Major Business
2.9.3 Bharat Serums and Vaccines Antivenom Product and Services
2.9.4 Bharat Serums and Vaccines Antivenom Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Bharat Serums and Vaccines Recent Developments/Updates
2.10 Serum Biotech
2.10.1 Serum Biotech Details
2.10.2 Serum Biotech Major Business
2.10.3 Serum Biotech Antivenom Product and Services
2.10.4 Serum Biotech Antivenom Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Serum Biotech Recent Developments/Updates
2.11 MicroPharm
2.11.1 MicroPharm Details
2.11.2 MicroPharm Major Business
2.11.3 MicroPharm Antivenom Product and Services
2.11.4 MicroPharm Antivenom Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 MicroPharm Recent Developments/Updates
3 Competitive Environment: Antivenom by Manufacturer
3.1 Global Antivenom Sales Quantity by Manufacturer (2020-2025)
3.2 Global Antivenom Revenue by Manufacturer (2020-2025)
3.3 Global Antivenom Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Antivenom by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Antivenom Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Antivenom Manufacturer 麻豆原创 Share in 2024
3.5 Antivenom 麻豆原创: Overall Company Footprint Analysis
3.5.1 Antivenom 麻豆原创: Region Footprint
3.5.2 Antivenom 麻豆原创: Company Product Type Footprint
3.5.3 Antivenom 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Antivenom 麻豆原创 Size by Region
4.1.1 Global Antivenom Sales Quantity by Region (2020-2031)
4.1.2 Global Antivenom Consumption Value by Region (2020-2031)
4.1.3 Global Antivenom Average Price by Region (2020-2031)
4.2 North America Antivenom Consumption Value (2020-2031)
4.3 Europe Antivenom Consumption Value (2020-2031)
4.4 Asia-Pacific Antivenom Consumption Value (2020-2031)
4.5 South America Antivenom Consumption Value (2020-2031)
4.6 Middle East & Africa Antivenom Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Antivenom Sales Quantity by Type (2020-2031)
5.2 Global Antivenom Consumption Value by Type (2020-2031)
5.3 Global Antivenom Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Antivenom Sales Quantity by Application (2020-2031)
6.2 Global Antivenom Consumption Value by Application (2020-2031)
6.3 Global Antivenom Average Price by Application (2020-2031)
7 North America
7.1 North America Antivenom Sales Quantity by Type (2020-2031)
7.2 North America Antivenom Sales Quantity by Application (2020-2031)
7.3 North America Antivenom 麻豆原创 Size by Country
7.3.1 North America Antivenom Sales Quantity by Country (2020-2031)
7.3.2 North America Antivenom Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Antivenom Sales Quantity by Type (2020-2031)
8.2 Europe Antivenom Sales Quantity by Application (2020-2031)
8.3 Europe Antivenom 麻豆原创 Size by Country
8.3.1 Europe Antivenom Sales Quantity by Country (2020-2031)
8.3.2 Europe Antivenom Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Antivenom Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Antivenom Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Antivenom 麻豆原创 Size by Region
9.3.1 Asia-Pacific Antivenom Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Antivenom Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Antivenom Sales Quantity by Type (2020-2031)
10.2 South America Antivenom Sales Quantity by Application (2020-2031)
10.3 South America Antivenom 麻豆原创 Size by Country
10.3.1 South America Antivenom Sales Quantity by Country (2020-2031)
10.3.2 South America Antivenom Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Antivenom Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Antivenom Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Antivenom 麻豆原创 Size by Country
11.3.1 Middle East & Africa Antivenom Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Antivenom Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Antivenom 麻豆原创 Drivers
12.2 Antivenom 麻豆原创 Restraints
12.3 Antivenom Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Antivenom and Key Manufacturers
13.2 Manufacturing Costs Percentage of Antivenom
13.3 Antivenom Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Antivenom Typical Distributors
14.3 Antivenom Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
CSL
Merck
BTG
Pfizer
Haffkine Bio-Pharmaceutical
Rare Disease Therapeutics
Flynn Pharma
Vins Bioproducts
Bharat Serums and Vaccines
Serum Biotech
MicroPharm
听
听
*If Applicable.
